Financial Disclosure Reg Should Exempt Publicly-Sponsored Studies - PhRMA
Executive Summary
Publicly-sponsored studies should be considered outside FDA's definition of "covered clinical studies" requiring financial disclosure information, the Pharmaceutical Research & Manufacturers of America told the agency in recent comments.
You may also be interested in...
CBER Lot Release Requirement Should Be Eliminated – PhRMA
The lot release requirement for biologics should be eliminated, the Pharmaceutical Research & Manufacturers of America maintained in comments submitted to the HHS Advisory Committee on Regulatory Reform
CBER Lot Release Requirement Should Be Eliminated – PhRMA
The lot release requirement for biologics should be eliminated, the Pharmaceutical Research & Manufacturers of America maintained in comments submitted to the HHS Advisory Committee on Regulatory Reform
Financial Disclosure Applies To Firms Providing Drugs For Public Studies
Pharmaceutical companies that contribute drugs to publicly funded studies used to support marketing applications will be responsible for collecting investigator financial interest information, an updated financial disclosure guidance notes.